Literature DB >> 16412062

Alveolar macrophage function is altered in patients with lung cancer.

D S Pouniotis1, M Plebanski, V Apostolopoulos, C F McDonald.   

Abstract

The alveolar macrophage (AM) is believed to be of central importance in the immune response against infection and tumour. We examined patients with lung cancer in order to evaluate the immuno-stimulatory potential of AM in lung cancer. Bronchoalveolar lavage fluid samples were obtained from patients with adenocarcinoma, squamous cell carcinoma, large cell undifferentiated lung carcinoma, small cell carcinoma and control subjects. AM were isolated and phagocytic function, flow cytometry and cytokine analysis were assessed. AM from patients with small and squamous cell carcinoma had impaired uptake in vitro of 40 nm fluorescent polystyrene beads. AM from patients with small, squamous and large cell undifferentiated carcinoma showed impaired uptake of 1000 nm fluorescent polystyrene beads. Secreted levels of TNF-alpha and IL-1 from AM of patients with small, squamous, and large cell undifferentiated carcinoma were decreased compared to controls. Secreted AM IL-6 levels were decreased in small and large cell undifferentiated carcinoma. AM from adenocarcinoma patients showed similar levels of IL-10, IL-6, IL-1 and TNF-alpha compared to controls. Phenotypic analysis demonstrated that patients with small cell carcinoma were the only group that showed a decrease in MHC class II surface expression. Surface expression of ICAM-1 and CD83 was decreased on AM from patients with large, squamous and small cell carcinoma compared to controls but not adenocarcinoma. Mannose receptor levels were only decreased on AM from patients with squamous and small cell carcinoma but not adenocarcinoma and large cell undifferentiated carcinoma. We conclude that there are type-specific alterations in uptake ability, cytokine secretion and phenotype of AM from lung cancer patients, which may result in an inability to stimulate anti-tumour immunity. The observed differences between lung cancer subgroups may explain previously reported inconsistencies in descriptions of AM characteristics in lung cancer.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16412062      PMCID: PMC1809587          DOI: 10.1111/j.1365-2249.2006.02998.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  44 in total

1.  Tumor-associated macrophages: the double-edged sword in cancer progression.

Authors:  Jeremy J W Chen; Yi-Chen Lin; Pei-Li Yao; Ang Yuan; Hsang-Yu Chen; Chia-Tung Shun; Meng-Feng Tsai; Chun-Houh Chen; Pan-Chyr Yang
Journal:  J Clin Oncol       Date:  2004-12-14       Impact factor: 44.544

2.  Defective cytostatic activity of pulmonary alveolar macrophages in primary lung cancer.

Authors:  C F McDonald; R C Atkins
Journal:  Chest       Date:  1990-10       Impact factor: 9.410

3.  The accessory cell function of human alveolar macrophages in specific T cell proliferation.

Authors:  G B Toews; W C Vial; M M Dunn; P Guzzetta; G Nunez; P Stastny; M F Lipscomb
Journal:  J Immunol       Date:  1984-01       Impact factor: 5.422

4.  The influence of dendritic cell infiltration and vascular endothelial growth factor expression on the prognosis of non-small cell lung cancer.

Authors:  Naoko Inoshima; Yoichi Nakanishi; Takahiro Minami; Miiru Izumi; Koichi Takayama; Ichiro Yoshino; Nobuyuki Hara
Journal:  Clin Cancer Res       Date:  2002-11       Impact factor: 12.531

5.  Cytokines in patients with lung cancer.

Authors:  D Matanić; Z Beg-Zec; D Stojanović; N Matakorić; V Flego; F Milevoj-Ribić
Journal:  Scand J Immunol       Date:  2003-02       Impact factor: 3.487

6.  Up-regulation of tumor interleukin-8 expression by infiltrating macrophages: its correlation with tumor angiogenesis and patient survival in non-small cell lung cancer.

Authors:  Jeremy J W Chen; Pei-Li Yao; Ang Yuan; Tse-Ming Hong; Chia-Tung Shun; Min-Liang Kuo; Yung-Chie Lee; Pan-Chyr Yang
Journal:  Clin Cancer Res       Date:  2003-02       Impact factor: 12.531

7.  Modulation of human alveolar macrophage tumoricidal activity by C-reactive protein.

Authors:  B P Barna; M J Thomassen; H P Wiedemann; M Ahmad; S D Deodhar
Journal:  J Biol Response Mod       Date:  1988-10

8.  Phagocytic activity of alveolar macrophages in patients with bronchogenic carcinoma.

Authors:  J D Gangemi; G N Olsen; C Fechter; J A Hightower; C T Bauguess; L Krech
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

9.  Induction of cytokine messenger RNA and secretion in alveolar macrophages and blood monocytes from patients with lung cancer receiving granulocyte-macrophage colony-stimulating factor therapy.

Authors:  M J Thomassen; M Ahmad; B P Barna; J Antal; H P Wiedemann; D P Meeker; J Klein; L Bauer; V Gibson; S Andresen
Journal:  Cancer Res       Date:  1991-02-01       Impact factor: 12.701

10.  Role of antitumor activity of alveolar macrophages in lung cancer patients.

Authors:  T Kuda; K Yasumoto; T Yano; H Nakahashi; K Sugimachi; K Nomoto
Journal:  Cancer Res       Date:  1987-04-15       Impact factor: 12.701

View more
  13 in total

Review 1.  Airway Macrophage and Dendritic Cell Subsets in the Resting Human Lung.

Authors:  Vineet Indrajit Patel; Jordan Patrick Metcalf
Journal:  Crit Rev Immunol       Date:  2018       Impact factor: 2.214

2.  Alveolar macrophage secretion of vesicular SOCS3 represents a platform for lung cancer therapeutics.

Authors:  Jennifer M Speth; Loka R Penke; Joseph D Bazzill; Kyung Soo Park; Rafael Gil de Rubio; Daniel J Schneider; Hideyasu Ouchi; James J Moon; Venkateshwar G Keshamouni; Rachel L Zemans; Vibha N Lama; Douglas A Arenberg; Marc Peters-Golden
Journal:  JCI Insight       Date:  2019-10-17

3.  Glucocorticoid-induced tumour necrosis factor receptor-related protein-mediated macrophage stimulation may induce cellular adhesion and cytokine expression in rheumatoid arthritis.

Authors:  E Bae; W-J Kim; Y-M Kang; K Suk; E-M Koh; H-S Cha; K-S Ahn; T-L Huh; W-H Lee
Journal:  Clin Exp Immunol       Date:  2007-03-15       Impact factor: 4.330

4.  Involvement of 27-hydroxycholesterol on the progression of non-small cell lung cancer via the estrogen receptor.

Authors:  Ikki Takada; Teruo Miyazaki; Yushi Goto; Hiroya Kanzawa; Taisuke Matsubara; Haruka Namikawa-Kanai; Shunsuke Shigefuku; Shotaro Ono; Eiji Nakajima; Yukio Morishita; Akira Honda; Kinya Furukawa; Norihiko Ikeda
Journal:  Am J Cancer Res       Date:  2022-09-15       Impact factor: 5.942

Review 5.  Alveolar Macrophage Polarisation in Lung Cancer.

Authors:  Saleh A Almatroodi; Christine F McDonald; Dodie S Pouniotis
Journal:  Lung Cancer Int       Date:  2014-05-08

6.  M2 polarization of macrophages facilitates arsenic-induced cell transformation of lung epithelial cells.

Authors:  Jiajun Cui; Wenhua Xu; Jian Chen; Hui Li; Lu Dai; Jacqueline A Frank; Shaojun Peng; Siying Wang; Gang Chen
Journal:  Oncotarget       Date:  2017-03-28

Review 7.  [HLA and immune of lung cancer].

Authors:  Huijuan Wang; Qinqin Wang
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2010-02

8.  Pulmonary toxicity and lung tumorigenic potential of surrogate metal oxides in gas metal arc welding-stainless steel fume: Iron as a primary mediator versus chromium and nickel.

Authors:  Lauryn M Falcone; Aaron Erdely; Rebecca Salmen; Michael Keane; Lori Battelli; Vamsi Kodali; Lauren Bowers; Aleksandr B Stefaniak; Michael L Kashon; James M Antonini; Patti C Zeidler-Erdely
Journal:  PLoS One       Date:  2018-12-26       Impact factor: 3.240

9.  MeDiA: Mean Distance Association and Its Applications in Nonlinear Gene Set Analysis.

Authors:  Hesen Peng; Junjie Ma; Yun Bai; Jianwei Lu; Tianwei Yu
Journal:  PLoS One       Date:  2015-04-27       Impact factor: 3.240

10.  NLRP3/Caspase-1 inflammasome activation is decreased in alveolar macrophages in patients with lung cancer.

Authors:  Ismini Lasithiotaki; Eliza Tsitoura; Katerina D Samara; Athina Trachalaki; Irini Charalambous; Nikolaos Tzanakis; Katerina M Antoniou
Journal:  PLoS One       Date:  2018-10-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.